ERYTECH Pharma S.A.
ERYTECH Pharma S.A. (ERYP.PA) Company Profile & Overview
Explore ERYTECH Pharma S.A.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
ERYTECH Pharma S.A. (ERYP.PA) Company Profile & Overview
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.